BC Innovations | Oct 27, 2016
Distillery Techniques

Disease models

TECHNOLOGY: Cell models Microglia-like cells derived from hPSCs could be used to model cellular pathologies in neurological diseases. The microglia-like cells were generated by plating hPSCs in a serum-free medium containing IL-34 and macrophage colony-stimulating...
BC Innovations | Oct 22, 2015
Distillery Therapeutics

Therapeutics: Interleukin-34 (IL-34)

Transplant INDICATION: Graft rejection Studies in rats, human blood and cell culture suggest IL-34 could help prevent cardiac graft rejection. In a rat model of allograft cardiac transplant, IL-34 levels in spleen and heart were...
BC Innovations | Aug 6, 2015
Distillery Therapeutics

Therapeutics: Interleukin-34 (IL-34)

Renal disease INDICATION: Renal damage Mouse and human sample studies suggest inhibiting IL-34 could help prevent kidney damage following ischemia/reperfusion injury. In kidney samples from kidney transplant patients, renal levels of IL-34 were higher in...
BC Innovations | Feb 7, 2013
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Macrophage colony-stimulating factor 1 (CSF1; M-CSF); IL-34; colony-stimulating factor 1 receptor (CSF1R; C-FMS; CD115) Mouse and cell culture studies suggest...
BioCentury | Mar 21, 2011
Product Development

Trapping a prime target

Five Prime Therapeutics Inc. bet that its novel fibroblast growth factor ligand trap would avoid the toxicity issues that have hampered development of FGF receptor antibodies and small molecule inhibitors. With Phase I data in...
BC Innovations | May 29, 2008
Targets & Mechanisms

FivePrime's Time

A paper published in Science has identified the previously unknown protein IL-34 as being involved in monocyte proliferation. 1 Besides opening new doors for autoimmune disease and cancer research, the finding provides proof of concept...
Items per page:
1 - 6 of 6